Oncology  Other

The Role of DDR and PARP inhibition (PARPi) in Oncology – BluePrints

Dr Violeta Serra

Dr Violeta Serra
Prof. Jonathan A. Ledermann

Prof. Jonathan A. Ledermann
Prof. Eric Pujade-Lauraine

Prof. Eric Pujade-Lauraine
Prof. Simon Boulton

Prof. Simon Boulton
Dr Mark J. O'Connor

Dr Mark J. O'Connor
Prof. Charlie Gourley

Prof. Charlie Gourley
Dr Judith Balmaña

Dr Judith Balmaña
Prof. Sibylle Loibl

Prof. Sibylle Loibl

Publication Date

Sep 2021

menu
temporal

DDR and PARPi BluePrint documents have been developed under the guidance of a Steering Committee with expertise in the field of DDR and PARP inhibition (PARPi).

 

These BluePrints are a reference guide to key aspects of PARPi and DDR and their role in oncology.

A variety of topics are covered, including the role of DDR in oncology, synthetic lethality, use of PARPi in oncology, efficacy and safety of currently approved PARP inhibitors, and the role of combination therapy with PARPi.

 

 

Dr Violeta Serra has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca and Tesaro. 

Prof. Jonathan A. Ledermann has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Clovis, Cristal Therapeutics, Pfizer, Roche and Seattle Genetics. 

Prof. Eric Pujade-Lauraine has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Clovis, Pfizer, Roche and Tesaro. 

Prof. Simon Boulton has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Artios Pharma Ltd.

Prof. Charlie Gourley has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Apera, Clovis, MSD, Nucana, Novartis, Roche, Sierra Oncology and Tesaro. 

Dr Judith Balmaña has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca. 

Prof. Sibylle Loibl has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Amgen, Novartis, Pfizer and Roche. 
Programme summary
Share this programme
This educational programme is supported by an Independent Educational Grant from AstraZeneca
I agree that this educational programme:

Was valuable to me

1/4

Other programmes of interest

video Video
Oncology 
The emerging role of artificial intelligence in precision oncology

Expert opinion on the clinical application of artificial intelligence (AI)

Experts
Prof. Albrecht Stenzinger
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Nov 2024
PRECISION ONCOLOGY CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Bayer.
podcast Podcast
Oncology 
BRAF-mutated CRC: from testing to treatment

Medical experts share insights and review key clinical trials

Experts
Prof. Sebastian Stintzing, Dr Thomas Winder
Endorsed by
Digestive Cancers Europe
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Nov 2024
GI CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Pierre Fabre. This content is not intended for HCPs within the UK.
other Other
Oncology 
Biomarker testing in NSCLC: patient and caregiver awareness and understanding

Findings from a global survey presented in a poster at ESMO 2024

Experts
Prof. Christian Rolfo, Prof. Fernando López-Ríos, Dr. Rodrigo Paredes, Amy Moore, Anne-Marie Baird, Shani Shilo
Endorsed by
LUNGevity
Lung Cancer Europe IASLC
The Israeli Lung Cancer Foundation ISLB
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2024
PRECISION ONCOLOGY CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Bayer.
podcast Podcast
Oncology Rare diseases 
Neuroendocrine tumours (NETs) shared decision-making: Exploring the patient journey and individualising treatments

Experts
Dr Mohid S Khan, Sally Jenkins
Endorsed by
CommNETs
NANETS
Neuroendocrine Cancer UK
The Healing NET Foundation
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Sep 2024
NET CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Ipsen
conference-update Conference update
Oncology 
ESMO 2024: New data on GI, lung, HCC, breast and GU cancers

Renowned medical experts share their insights into new data presented at ESMO 2024

  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2024
COR2ED Non-accredited Independent Medical Education
animated-video Animated Video

Episode

1

of 1

episode
Oncology 
Precision oncology in prostate cancer: tips for optimal genomic testing

From sample collection through to diagnostic modalities 

Experts
Dr Alexander Wyatt
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2024
PRECISION ONCOLOGY CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
Explore all programmes